Weight Gain Prevention Drug Fails In Trial

A story in the Globes just announced the failure of a drug being developed to prevent the weight gain associated with atypical neuroleptic drugs to do any better than a placebo, Obecure obesity drug fails trial.

Histalean was given in combination with Eli Lilly’s (NYSE: LLY) antipsychotic drug, Zyprexa, which is known to cause weight gain. In previous trials, Obecure was able to show that patients taking Zyprexa gained less weight when also taking Histalean than when taking Zyprexa alone.

Get that, gained less weight. Such was in the past, but more recently:

In the current trial using a higher dosage of Histalean, Obecure was unable to repeat the results.

Bio-light, the company developing Histalean, is repeating trials with a lower dosage to see if dosage might be at the root of this failure.

Eli Lilly, which partly financed the first trial of Histalean, on the grounds that ameliorating the side effects of Zyprexa would help product sales, is no longer involved in Histalean.

If you have any knowledge about this issue, you are probably aware that obesity is only one of a number of ill health conditions associated with a metabolic syndrome caused by the newer atypical neuroleptic drugs of which Zyprexa is an example. This metabolic syndrome has been credited with being the chief reason people in mental health treatment are dying on average 25 years earlier than the rest of the population.

Have we got a better argument for advancing methods of treatment that don’t involve the use of neuroleptic drugs, atypical or otherwise!? Well, actually, we do. Some studies have indicated that these drugs are at best ineffective, and at worst impeditive, if not preventive, to the process of complete recovery from serious life crises.

If there’s a lesson to be learned here it’s that health and fitness can’t be found in a pill bottle. Of course, this is a lesson some people are lax to pick up as it would jeopardize the enormous profit making power of pharmaceutical companies.